Alnylam PharmaceuticalsALNY
About: Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Employees: 2,230
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
54% more first-time investments, than exits
New positions opened: 97 | Existing positions closed: 63
25% more capital invested
Capital invested by funds: $34.2B [Q1] → $42.9B (+$8.63B) [Q2]
19% more repeat investments, than reductions
Existing positions increased: 253 | Existing positions reduced: 212
4% more funds holding
Funds holding: 617 [Q1] → 639 (+22) [Q2]
3.03% more ownership
Funds ownership: 97.8% [Q1] → 100.83% (+3.03%) [Q2]
10% less funds holding in top 10
Funds holding in top 10: 10 [Q1] → 9 (-1) [Q2]
17% less call options, than puts
Call options by funds: $122M | Put options by funds: $147M
Research analyst outlook
18 Wall Street Analysts provided 1 year price targets over the past 3 months
18 analyst ratings
HC Wainwright & Co. Patrick Trucchio | 26%upside $570 | Buy Maintained | 7 Aug 2025 |
JP Morgan Jessica Fye | 5%upside $475 | Overweight Maintained | 6 Aug 2025 |
Oppenheimer Leland Gershell | 9%upside $490 | Outperform Upgraded | 4 Aug 2025 |
Scotiabank Greg Harrison | 0%downside $450 | Sector Outperform Maintained | 1 Aug 2025 |
UBS Eliana Merle | 22%upside $550 | Buy Maintained | 1 Aug 2025 |
Financial journalist opinion
Based on 14 articles about ALNY published over the past 30 days
